Immune Checkpoint Inhibitor-Related Adrenal Insufficiency

被引:2
|
作者
Cherry, Grace [1 ]
机构
[1] UCLA, Hlth Melanoma Program, 100 Med Plaza,Suite 550, Los Angeles, CA 90095 USA
关键词
Oncology nurses; Immune Checkpoint Inhibitor-Related Adrenal; Insufficiency; Case study; Evidence-cased; Clinical reflection; DIAGNOSIS;
D O I
10.1016/j.soncn.2021.151131
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: It is an exciting time in oncology nursing as new treatments are continually emerging to improve oncological outcomes for people affected by cancer. Immunotherapy is one such innovation in contemporary oncology practice, but the side effects of its treatment can be life threatening. Oncology nurses must be educated in the early identification of life-threatening side effects, and deliver evidence-based interventions to manage consequences of therapy such as, immune checkpoint inhibitor-related adrenal insufficiency. Data Source: This article utilizes a case study to emphasize the need for early identification and interventions for clinical management of immunotherapy related adrenal insufficiency. A review of the current evidence is included to provide recommendations for oncology nurses who are involved in providing care for people affected by cancer receiving immunotherapy. Implications for Nursing Practice: Oncology nurses are the frontline caregivers to assess, recognize, so that early intervention and treament can lead to optimal patient outcomes. Conclusion: Adrenal insufficiency is a life-threatening condition that is difficult to diagnose but if recognized early, morbidity can be prevented, quality of life improved, treatment initiated and life saving immunotherapy treatment can safely continue. Oncology nurses play an active role in ensuring the safe administration of immunotherapy by recognizing this important immune related adverse event. I would like to give credit to Patricia Jakel, RN, MSN, UCLA CNS and Dr. Melissa Lechner, UCLA endocrinologist for their invaluable input in this article. (c) 2021 Published by Elsevier Inc.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Management of immune checkpoint inhibitor-related dermatologic adverse events
    Si, Xiaoyan
    He, Chunxia
    Zhang, Li
    Liu, Xiaowei
    Li, Yue
    Wang, Hanping
    Guo, Xiaoxiao
    Zhou, Jiaxin
    Duan, Lian
    Wang, Mengzhao
    THORACIC CANCER, 2020, 11 (02) : 488 - 492
  • [42] Efficacy of dupilumab in patients with immune checkpoint inhibitor-related pruritus
    Shatokhina, E.
    Kruglova, L.
    Polonskaia, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E101 - E102
  • [43] Checkmate? A Rare Case of Immune Checkpoint Inhibitor-Related AKI
    Sathiyaraj, Steffi
    Varela, Daniel
    Garcia, Leonardo Pozo
    Manllo, Sergio A. Trevino
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 786 - 786
  • [44] Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency
    Mishra, Tushar
    He, Gong
    Sreeram, Kalyan
    Rauf, Mohammad
    Subahi, Ahmed
    Hazem, Mariam
    AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (05) : E626 - E627
  • [46] Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature
    Deng, Yisi
    Huang, Manling
    Deng, Runpei
    Wang, Jun
    MEDICINE, 2024, 103 (12) : E37562
  • [47] Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
    Wang, Yinghong
    Abu-Sbeih, Hamzah
    Mao, Emily
    Ali, Noman
    Qiao, Wei
    Van Anh Trinh
    Zobniw, Chrystia
    Johnson, Daniel Hartman
    Samdani, Rashmi
    Lum, Phillip
    Shuttlesworth, Gladis
    Blechacz, Boris
    Bresalier, Robert
    Miller, Ethan
    Thirumurthi, Selvi
    Richards, David
    Raju, Gottumukkala
    Stroehlein, John
    Diab, Adi
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (08) : 1695 - 1705
  • [48] Incidence and outcomes of immune checkpoint inhibitor-related myositis.
    Aldrich, Jeffrey
    Pundole, Xerxes
    Tummala, Sudhakar
    Andersen, Clark
    Shoukier, Mahran
    Abdel-Wahab, Noha
    Palaskas, Nicolas
    Deswal, Anita
    Suarez-Almazor, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis
    Asada, Mizuho
    Mikami, Takahisa
    Niimura, Takahiro
    Zamami, Yoshito
    Uesawa, Yoshihiro
    Chuma, Masayuki
    Ishizawa, Keisuke
    ONCOLOGY, 2021, 99 (04) : 256 - 259
  • [50] Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
    Lee, Karla A.
    Shaw, Heather
    Bataille, Veronique
    Nathan, Paul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)